Nicholson Garry A

SEC source: 0001193125-26-236854 · ownership.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Voting Common Stock · 67,000 shares

Expires 2036-05-20

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

SEC source: 0001640861-26-000001 · form4-04232026_080444.xml · derivative · entry 5

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F7 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F8 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

SEC source: 0001640861-26-000001 · form4-04232026_080444.xml · derivative · entry 4

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,500 shares

Expires 2035-06-01

F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F5 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

SEC source: 0001640861-26-000001 · form4-04232026_080444.xml · derivative · entry 3

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,335 shares

Expires 2034-05-22

F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F1 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-26-000001 · form4-04232026_080444.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,500 shares

Expires 2033-06-21

F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F1 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-26-000001 · form4-04232026_080444.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,900 shares

Expires 2032-09-11

F2 · price: On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F3 · price: Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement.

F4 · price: Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes.

F1 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 6

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,335

Underlying: Common Stock · 32,335 shares

Expires 2034-05-22

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 5

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,335 shares

Expires 2034-05-22

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 4

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2033-06-21

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 3

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,500 shares

Expires 2033-06-21

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,900

Underlying: Common Stock · 33,900 shares

Expires 2032-09-11

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0001640861-25-000004 · form4-11072025_111124.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,900 shares

Expires 2032-09-11

F1 · kind: On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).

F2 · kind: (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: The options are fully vested.

SEC source: 0000950170-25-093057 · ownership.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Voting Common Stock · 67,000 shares

Expires 2035-06-30

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

SEC source: 0001415889-25-015622 · form4-06042025_090656.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date") , subject to the Reporting Person's provision of services to the Issuer on each vesting date. On the RSU Vesting Date, pursuant to the Reporting Person's election, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of shares of the Issuer's Common Stock on the earlier of the calendar year 2030 or the Reporting Person's separation with the Issuer. Notwithstanding the aforementioned deferral period, from and after the RSU Vesting Date, the deferred stock units may settle earlier upon the Reporting Person's death, disability, or separation from service with the Issuer, or upon the occurrence of an "unforeseeable emergency," as that term is defined under the Issuer's deferred compensation plan.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.

SEC source: 0001415889-25-015622 · form4-06042025_090656.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-01

F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.

SEC source: 0000950170-24-107797 · ownership.xml · derivative · entry 5

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2032-06-23

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

SEC source: 0000950170-24-107797 · ownership.xml · derivative · entry 4

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2033-06-15

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

SEC source: 0000950170-24-107797 · ownership.xml · derivative · entry 3

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2034-06-13

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.

SEC source: 0000950170-24-107797 · ownership.xml · nonDerivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.

SEC source: 0000950170-24-107797 · ownership.xml · nonDerivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,389

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").

F2 · kind: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").

F2 · price: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.

SEC source: 0001562180-24-005078 · primarydocument.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-13

F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director.

SEC source: 0001562180-24-005078 · primarydocument.xml · nonDerivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,389

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board.

F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock.

F3 · balance_after: Represents (i) 14,389 shares of common stock; (ii) 10,000 RSUs from award granted on June 15, 2023; and (iii) 10,000 RSUs from award granted on June 13, 2024.

SEC source: 0000950170-24-073692 · ownership.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,750

Underlying: Voting Common Stock · 23,750 shares

Expires 2034-06-11

F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable with respect to one-third of the shares on June 12, 2025, with the balance vesting thereafter in 24 equal monthly installments, subject to the Reporting Person's continued service at each such time.

SEC source: 0000950170-24-073692 · ownership.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,500

Underlying: Voting Common Stock · 47,500 shares

Expires 2034-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

SEC source: 0001415889-24-014723 · form4-05282024_100500.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,335

Underlying: Common Stock · 32,335 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on June 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001140361-23-031195 · form4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders.

SEC source: 0001209191-23-039826 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 22, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001562180-23-005264 · primarydocument.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-15

F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director.

SEC source: 0001562180-23-005264 · primarydocument.xml · nonDerivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,389

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board.

F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock.

F3 · balance_after: Represents (i) 4,389 shares of common stock; (ii) 10,000 RSUs from award granted on June 23, 2022; and (iii) 10,000 RSUs from award granted on June 15, 2023.

SEC source: 0001209191-22-049988 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,900

Underlying: Common Stock · 33,900 shares

Expires 2032-09-11

F1 · derivative.exercise_date: The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on October 12, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-22-046291 · doc4.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,500 shares

Expires 2031-06-01

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

SEC source: 0001209191-22-046291 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,400 shares

Expires 2030-01-21

F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

SEC source: 0001562180-22-005353 · primarydocument.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-06-23

F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.

SEC source: 0001562180-22-005353 · primarydocument.xml · nonDerivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,389

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.

F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock

F3 · balance_after: Represents 4,389 shares of common stock and 10,000 restricted stock units

SEC source: 0001567619-22-013370 · doc1.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders.

SEC source: 0001567619-21-012671 · doc1.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,250

Underlying: Common Stock · 14,250 shares

Expires 2031-06-23

F1 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders.

SEC source: 0001562180-21-004393 · primarydocument.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,620

Underlying: Common Stock · 19,620 shares

Expires 2031-06-17

F3 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director.

SEC source: 0001562180-21-004393 · primarydocument.xml · nonDerivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,389

F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 17, 2021, subject to the Reporting Person's continued service as a director.

F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock

SEC source: 0001209191-21-038331 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2031-06-01

F1 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant.

SEC source: 0001209191-21-027409 · doc4.xml · derivative · entry 4

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F2 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027409 · doc4.xml · derivative · entry 3

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F2 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027409 · doc4.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F2 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-21-027409 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F1 · price: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.

F2 · derivative.expiration_date: Not applicable.

SEC source: 0001209191-20-037411 · doc4.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,400

Underlying: Common Stock · 23,400 shares

Expires 2030-01-21

F1 · kind: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

F1 · price: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

F1 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

SEC source: 0001209191-20-037411 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2030-01-21

F1 · kind: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

F1 · price: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

F1 · derivative.exercise_date: The reported transaction involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 22, 2020 and provides for vesting of the shares in a series of 36 successive equal monthly installments over the three year period measured from January 22, 2020.

SEC source: 0001209191-20-036298 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 11, 2020, subject to the Reporting Person's continued service as a director.

SEC source: 0001123292-20-000878 · edgar.xml · derivative · entry 2

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2030-06-10

F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 11, 2021.

SEC source: 0001123292-20-000878 · edgar.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,083

Underlying: Common Stock · 16,083 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.

SEC source: 0001209191-20-029832 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-05-13

F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 14, 2021 or (ii) the day before the 2021 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date.

SEC source: 0001209191-20-004648 · doc4.xml · derivative · entry 1

Nicholson Garry A · CIK 0001640861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-01-21

F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant.